Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;20(6):372-9.
doi: 10.1002/rmv.664.

CMV in critically ill patients: pathogen or bystander?

Ajit P Limaye  1 , Michael Boeckh
Affiliations
Review

CMV in critically ill patients: pathogen or bystander?

Ajit P Limaye et al. Rev Med Virol. 2010 Nov.

Abstract

Despite broad variability in study populations, methodologies for CMV detection, and analytic methods used, multiple studies have documented frequent CMV infection in non-immunocompromised adults with critical illness due to a variety of causes. Higher rates of CMV infection in studies of seropositive patients suggest that reactivation of latent infection rather than primary infection is the main mechanism in this setting. Risk factors for CMV reactivation (other than seropositivity) have not been clearly defined and there does not appear to be a consistent association with severity of illness. Furthermore, CMV reactivation in this setting has been associated with important adverse clinical outcomes, including increased duration of mechanical ventilation, longer length of stay and all-cause mortality. There are several biologically plausible mechanisms that could link CMV reactivation with adverse outcomes, including: direct lung injury (CMV pneumonia), amplification of inflammation systemically and within the lung, or predisposition to other nosocomial infections, but clinical data in the ICU setting are limited. Further observational studies are unlikely to significantly advance our understanding of the role of CMV in critically ill patients. Given the significant impact of critical illness, limited current therapeutic options, the availability of generally well-tolerated antiviral options for CMV, and the clinical data supporting a possible pathogenic role for CMV, there is a strong rationale for a randomised controlled trial of CMV prevention as a novel means of improving the outcomes of critically ill patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative incidence of CMV viremia in CMV seropositive, non-immunocompromised adults in the ICU [3].
Figure 2
Figure 2
Impact of different ganciclovir regimens on reactivation of CMV (A) and pulmonary fibrosis (B) in a murine model of CMV reactivation and lung injury induced by cecal ligation and puncture [51].
See this image and copyright information in PMC

References

    1. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med. 2009 Aug;37(8):2350–2358. - PubMed
    1. Hamprecht K, Baumeister A, Beck R, Haeberle H, Heininger A. The lung as a central compartment of active CMV infection. Inflammation Research Supplement 2. 2007:S242. (Abstract A383)
    1. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008 Jul 23;300(4):413–422. - PMC - PubMed
    1. Domart Y, Trouillet JL, Fagon JY, Chastre J, Brun-Vezinet F, Gibert C. Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest. 1990 Jan;97(1):18–22. - PubMed
    1. Papazian L, Fraisse A, Garbe L, et al. Cytomegalovirus. An unexpected cause of ventilator-associated pneumonia. Anesthesiology. 1996 Feb;84(2):280–287. - PubMed

Publication types